OPC-21268

• CAT Number: I008477
• CAS Number: 131631-89-5
• Molecular Formula: C26H31N3O4
• Molecular Weight: 449.551
• Purity: ≥95%
• Synonyms: OPC-21268; OPC21268; OPC 21268;N-(3-(4-(4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carbonyl)phenoxy)propyl)acetamide
• Target: Vasopressin Receptor
• Solubility: Soluble in DMSO
• Storage: Store at +4C
• IUPAC Name: N-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide
• InChI: InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)
• InChIKey: KSNUCNRMDYJBKT-UHFFFAOYSA-N
• SMILES: CC(=O)NCCCOC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3C(=O)CCC4=CC=CC=C43

OPC-21268 is a vasopressin 1 receptor antagonist potentially for the treatment of heart failure and hypertension.

Reference

1:Corrigendum to: key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268 (FEBS 23227). Shinouraa2 H, Takea2 H, Itohb S, Hirasawaa A, Inouec K, Ohnoc Y, Hashimotod K, Tsujimotoa G.FEBS Lett. 2000 Jun 2;474(2-3):257. No abstract available. PMID: 10838096 Free Article2:Key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268. Shinoura H, Take H, Itoh S, Hirasawa A, Inoue K, Ohno Y, Hashimoto K, Tsujimoto G.FEBS Lett. 2000 Jan 28;466(2-3):255-8. Erratum in: FEBS Lett 2000 Jun 2;474(2-3):257. PMID: 10682838 Free Article3:Protective effect of a vasopressin-1 selective antagonist, OPC-21268, against ethanol-induced damage of the rat gastric wall. Sugimoto I, Narimiya N, Odagiri M, Ohnishi A, Tanaka T.Dig Dis Sci. 1999 Mar;44(3):503-9. PMID: 10080141 4:Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats. Bemana I, Nagao S.Neurosurgery. 1999 Jan;44(1):148-54; discussion 154-5. PMID: 9894975 5:Effects of OPC-21268, a vasopressin V1-receptor antagonist, on expression of growth factors from glomeruli in spontaneously hypertensive rats. Otsuka F, Ogura T, Yamauchi T, Oishi T, Hashimoto M, Mimura Y, Makino H.Regul Pept. 1997 Oct 31;72(2-3):87-95. PMID: 9652981 6:The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes. Kawano Y, Matsuoka H, Nishikimi T, Takishita S, Omae T.Am J Hypertens. 1997 Nov;10(11):1240-4. PMID: 9397242 7:OPC-21268, an orally effective, nonpeptide arginine vasopressin V1 receptor antagonist reduces vasogenic brain edema. Bemana I, Takahashi E, Nakamura T, Kuyama H, Nagao S.Acta Neurochir Suppl. 1997;70:194-7. PMID: 9416320 8:In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260. Mimura Y, Ogura T, Hayakawa N, Otsuka F, Hashimoto M, Yamauchi T, Makino H, Ogawa N.Nephron. 1997;76(3):331-6. PMID: 9226235 9:Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Kurihara I, Saito T, Obara K, Shoji Y, Hirai M, Soma J, Sato H, Imai Y, Abe K.Nephron. 1996;73(4):629-36. PMID: 8856262 10:Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium. Atke A, Vilhardt H, Hauzerova L, Barth T, Andersen LF.Eur J Pharmacol. 1995 Jul 25;281(1):63-8. PMID: 8566118